Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas, F
Miranda Rota, E
Ben Aissa, A
Werner Sunderland, M
Melanoma TRACERx Consortium
Renal TRACERx Consortium
Lung TRACERx Consortium
MetadataShow full item record
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We demonstrated that CD25 expression is largely restricted to tumor-infiltrating Treg cells in mice and humans. While existing anti-CD25 antibodies were observed to deplete Treg cells in the periphery, upregulation of the inhibitory Fc gamma receptor (FcγR) IIb at the tumor site prevented intra-tumoral Treg cell depletion, which may underlie the lack of anti-tumor activity previously observed in pre-clinical models. Use of an anti-CD25 antibody with enhanced binding to activating FcγRs led to effective depletion of tumor-infiltrating Treg cells, increased effector to Treg cell ratios, and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies promoted complete tumor rejection, demonstrating the relevance of CD25 as a therapeutic target and promising substrate for future combination approaches in immune-oncology.
Version of record
Fc gamma receptors
inhibitory Fc receptor
regulatory T cells
Cell Line, Tumor
Immunoglobulin Fc Fragments
Interleukin-2 Receptor alpha Subunit
Programmed Cell Death 1 Receptor
Melanoma and Kidney Cancer
License start date
Immunity, 2017, 46 (4), pp. 577 - 586
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. Powles, T; Huddart, RA; Elliott, T; Sarker, S-J; Ackerman, C; Jones, R; Hussain, S; Crabb, S; Jagdev, S; Chester, J; Hilman, S; Beresford, M; Macdonald, G; Santhanam, S; Frew, JA; Stockdale, A; Hughes, S; Berney, D; Chowdhury, S (2017-01)Purpose To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in human epidermal growth factor receptor (HER) 1/HER2-positive metastatic urothelial bladder cancer (UBC). Methods Patients ...
Dillon, MT; Barker, HE; Pedersen, M; Hafsi, H; Bhide, SA; Newbold, KL; Nutting, CM; McLaughlin, M; Harrington, KJ (2017-01)AZD6738 is an orally active ATR inhibitor (ATRi) currently in phase I clinical trials. We found in vitro growth inhibitory activity of this ATRi in a panel of human cancer cell lines. We demonstrated radiosensitization by ...
Fribbens, C; O'Leary, B; Kilburn, L; Hrebien, S; Garcia-Murillas, I; Beaney, M; Cristofanilli, M; Andre, F; Loi, S; Loibl, S; Jiang, J; Bartlett, CH; Koehler, M; Dowsett, M; Bliss, JM; Johnston, SR; Turner, NC (2016-09)ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that represent ...